Recent News

By Category: Research

UTMB awarded $4.8M to develop vaccine for Junin virus

GALVESTON — Scientists at the University of Texas Medical Branch and the Scripps Research Institute in La Jolla, Calif., have received a five-year $4.8 million grant from the National Institute of Allergy and Infectious Diseases to produce a new, safer vaccine candidate for Junin virus, a deadly Argentine hemorrhagic fever pathogen identified as a potential Read More »

April 20, 2011
| Filed under North America, Countermeasures, and Research
Share

Antibiotics Cure Anthrax in Animal Model

ScienceDaily — In the absence of early antibiotic treatment, respiratory anthrax is fatal. The 2001 bioterrorism attacks in the US killed four people, out of 22 infected (10 of them with respiratory anthrax), despite massive antibiotic administration, probably because therapy did not begin until the disease had reached the fulminant stage. But a multi-agent prophylaxis Read More »

April 20, 2011
| Filed under North America and Research
Share

DTRA is supporting a clinical study now underway by the USAMRIID to evaluate a vaccine against ricin toxin

The Defense Threat Reduction Agency (DTRA) is supporting a clinical study now underway by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate a vaccine against ricin toxin. This is a critical milestone for DTRA’s Chemical/Biological Technologies Directorate Translational Medicine Science & Technology Division (CBM) to support “first in human” evaluations of Read More »

April 19, 2011
| Filed under North America, Countermeasures, and Research
Share

Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines

(Duke University Medical Center) The Duke Human Vaccine Institute today announced a collaboration and strategic agreement with Novartis Vaccines and Diagnostics to enable the rapid development of a vaccine and accelerate preparedness in case of a pandemic virus threat such as pandemic influenza.

April 15, 2011
| Filed under North America, Countermeasures, Public Health, and Research
Share

U.S. Funds Tularemia, Botulism Treatment Research

The Canadian biopharmaceutical firm DiaMedica on Monday said it had entered a deal with the U.S. National Institute of Allergy and Infectious Diseases for continued study of a potential tularemia countermeasure (see GSN, April 5, 2010). The antibody under investigation inhibits a specific protein, a process that “has previously been shown to suppress the lethal Read More »